Repligen Co. (NASDAQ:RGEN - Free Report) - Analysts at William Blair reduced their Q1 2025 earnings per share (EPS) estimates for Repligen in a report released on Friday, February 21st. William Blair analyst M. Larew now forecasts that the biotechnology company will earn $0.33 per share for the quarter, down from their prior forecast of $0.38. The consensus estimate for Repligen's current full-year earnings is $1.72 per share. William Blair also issued estimates for Repligen's Q2 2025 earnings at $0.45 EPS, Q3 2025 earnings at $0.44 EPS, Q4 2025 earnings at $0.48 EPS, FY2025 earnings at $1.71 EPS, Q1 2026 earnings at $0.48 EPS, Q2 2026 earnings at $0.59 EPS, Q3 2026 earnings at $0.58 EPS, Q4 2026 earnings at $0.64 EPS and FY2026 earnings at $2.28 EPS.
Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%.
Several other analysts also recently issued reports on RGEN. Wolfe Research initiated coverage on Repligen in a research report on Thursday, November 14th. They issued a "peer perform" rating on the stock. StockNews.com downgraded Repligen from a "hold" rating to a "sell" rating in a research report on Friday, February 21st. Canaccord Genuity Group increased their target price on Repligen from $165.00 to $170.00 and gave the company a "hold" rating in a research note on Friday, February 21st. JPMorgan Chase & Co. raised their price objective on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Finally, HC Wainwright reaffirmed a "buy" rating and set a $180.00 target price on shares of Repligen in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Repligen currently has an average rating of "Moderate Buy" and a consensus target price of $181.00.
Read Our Latest Analysis on RGEN
Repligen Price Performance
Repligen stock traded down $6.27 during trading hours on Monday, hitting $156.54. The stock had a trading volume of 438,659 shares, compared to its average volume of 616,050. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The stock has a market capitalization of $8.77 billion, a price-to-earnings ratio of -306.94, a PEG ratio of 4.54 and a beta of 0.99. Repligen has a 1-year low of $113.50 and a 1-year high of $203.13. The stock's fifty day moving average is $155.68 and its two-hundred day moving average is $148.65.
Institutional Trading of Repligen
A number of large investors have recently made changes to their positions in RGEN. Ballentine Partners LLC boosted its stake in shares of Repligen by 4.0% during the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company's stock worth $270,000 after buying an additional 72 shares during the last quarter. CIBC Asset Management Inc increased its stake in Repligen by 5.0% in the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company's stock valued at $246,000 after acquiring an additional 81 shares during the last quarter. MML Investors Services LLC increased its stake in Repligen by 2.7% in the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company's stock valued at $503,000 after acquiring an additional 89 shares during the last quarter. GAMMA Investing LLC increased its stake in Repligen by 15.2% in the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company's stock valued at $98,000 after acquiring an additional 90 shares during the last quarter. Finally, Louisiana State Employees Retirement System grew its stake in shares of Repligen by 0.7% during the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company's stock worth $2,087,000 after buying an additional 100 shares during the last quarter. Institutional investors own 97.64% of the company's stock.
About Repligen
(
Get Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Featured Articles
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
